Aarthi Scans & Labs and Origin Medical Advance AI-Enabled Prenatal Ultrasound

IMT News Desk
IMT News Desk
· 3 min read
Aarthi Scans & Labs and Origin Medical are advancing AI-enabled prenatal ultrasound to deliver faster, more consistent and accessible maternal-fetal care

Aarthi Scans & Labs and Origin Medical Research Lab India Private Limited, the research and development arm of Origin Medical, have announced an ongoing collaboration to enhance the quality and accessibility of prenatal ultrasound care through artificial intelligence. Over the past five years, the two organisations have jointly developed and validated AI solutions tailored for maternal- fetal imaging in high-volume clinical environments, with the goal of ensuring that expecting mothers receive consistent, high-quality prenatal assessments irrespective of where they seek care.

The collaboration focuses on critical steps in the prenatal ultrasound workflow, including automated image capture, anatomical landmark detection, real-time image quality assessment and fetal biometry. These capabilities are designed to streamline workflows, reduce inter-operator variability and support clinicians in delivering more standardised prenatal care. By integrating AI-driven guidance and feedback into routine scans, the partners aim to help radiologists and fetal medicine specialists complete comprehensive anatomical surveys more efficiently, while maintaining adherence to international practice guidelines.

“Prenatal ultrasound plays a critical role in monitoring fetal development and enabling timely clinical decisions during pregnancy. However, ensuring consistency and quality in fetal imaging across high-volume and diverse healthcare settings continues to be a challenge,” said Dr Arunkumar Govindarajan, Radiologist and Executive Director, Aarthi Scans & Labs. He added that the collaboration with Origin Medical Research Lab is focused on closing this gap through clinically validated AI solutions that support specialists in delivering more standardised and accurate prenatal assessments, with the broader objective of improving access to high-quality maternal healthcare in a rapidly growing market like India.

The outcomes of the joint work, carried out in collaboration with additional clinical and research partners, have been presented at leading international forums such as the ISUOG World Congress and the Fetal Medicine Foundation World Congress. Across multiple studies, the AI systems have demonstrated strong performance in identifying and assessing complete fetal anatomy, including critical regions like the fetal central nervous system, underscoring their potential role in strengthening anomaly detection in routine clinical practice.

As part of the collaboration, the partners have developed AI systems with automated image capture and feedback features that help clinical teams acquire complete anatomical surveys more efficiently, thereby reducing scan times and improving the overall patient experience. The systems also incorporate real-time image-quality and view-completeness checks, providing immediate feedback to ensure that required anatomical views are captured in line with international standards. In addition, automated fetal measurement tools are intended to improve the consistency of fetal biometry and reduce human-to-human variability in prenatal ultrasound assessments across different centres.

“Aarthi Scans & Labs has been one of our first and foundational partners from day one, and their clinical rigour, scale and commitment to innovation have been central to the progress we have made in AI-driven prenatal imaging,” said Sripad Krishna Devalla, co-founder and CEO of Origin Medical. He noted that Origin Medical Research Lab, as the dedicated research and development arm of Origin Medical, places partnerships like this at the core of its work translating real-world clinical data and insights into AI solutions that are validated, scalable and clinically meaningful, and directly shaping the technologies that Origin Medical is bringing to prenatal care settings globally.

Read Next

India’s first focused health AI Conclave unites doctors and AI experts
Featured Article
July 10, 2026

India’s first focused health AI Conclave unites doctors and AI experts

• Global Healthcare Academy hosts HAI Conclave 2026, India’s first national platform dedicated to Healthcare and Artificial Intelligence • Landmark Bengaluru conference brings together healthcare leaders and AI experts to explore how Artificial Intelligence can make healthcare faster, safer and more accessible while keeping patients at the centre of every decision The inaugural edition of the HAI Conclave […]
Article by: IMT News Desk
Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026
News
July 10, 2026

Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026

Fischer Medical Ventures Limited (FMVL) has announced that its strategic partner, Nanyang Biologics, has achieved a major international milestone with its AI-powered molecular research platform, NYB.AI, being featured in the opening showcase at NVIDIA GTC Taiwan 2026, ahead of the keynote address by NVIDIA Founder and CEO Jensen Huang. The recognition places NYB.AI among a […]
Article by: IMT News Desk
Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs
News
July 10, 2026

Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs

Indian pharmaceutical companies are expected to report healthy revenue growth in the first quarter of FY27, but margins are likely to compress as sector profitability comes under pressure. In a recent preview note, Goldman Sachs said it anticipates around 185 basis points year-on-year margin decline for the sector in the June quarter, driven primarily by […]
Article by: IMT News Desk
Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue
News
July 10, 2026

Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue

Dr Reddy’s Laboratories has announced a delay in commercial supplies of its semaglutide product after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug. The company said it has initiated an investigation into the root cause and is taking corrective measures […]
Article by: IMT News Desk